Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Merck Sharp & Dohme LLC and Seagen
Description:
Bladder cancer, also known as urothelial carcinoma, is the ninth
leading cause of cancer death in the United States. According to the
American Cancer Society, there were an estimated 82,290 new cases of
bladder cancer and 17,100 deaths in the United States in 2022.
Before the advent of new treatments in recent years, the basic
management of this illness has remained unchanged for decades.
Long-term survival for people diagnosed with advanced bladder cancer
is poor, with approximately 5% of patients with metastatic bladder
cancer surviving for 5 years or more. As the role of the immune
system in oncogenesis and therapy has become clearer across cancer
types, new approaches emerged with important benefits in metastatic
bladder cancer, which led to the introduction of immune checkpoint
inhibitors. However, when those options fail, and when patients are
ineligible for cisplatin-containing chemotherapy, options are sparse
to manage this difficult disease. Fortunately for patients with
metastatic bladder cancer, new agents, including antibody-drug
conjugates both alone and in combination with immunotherapies, have
recently emerged for patients with metastatic bladder cancer,
especially in patients who are ineligible for cisplatin-containing
chemotherapy. It is for this reason that medical directors,
oncologists, practicing physicians, nurse case managers and other
healthcare professionals must be educated on these emerging options
and strategies for their implementation into the treatment paradigm,
which will ultimately improve patient outcomes in the metastatic
bladder cancer patient population.
Upon completion of this
activity, participants will be able to:
-
Explore the clinical and economic
burden of locally advanced/metastatic urothelial cancer (mUC),
including factors that contribute to poor prognosis and
increased costs
-
Compare the current standard
treatment options for locally advanced/mUC including their
benefits, limitations, and recommendations for use
-
Analyze the mechanisms, efficacy,
and safety data for current and emerging agents and combination
regimens to inform treatment selection and sequencing strategies
-
Examine the evolving role and impact
of anti-PD-1 therapy in the management of metastatic bladder
cancer
-
Assess the current role and impact
of antibody-drug conjugates, both alone and in combination with
immunotherapies, in the management of locally advanced/mUC
-
Examine the managed care
considerations of current and emerging therapies, including
antibody-drug conjugates and checkpoint inhibitors, to help
improve the clinical and economic burden of patients with
locally advanced/mUC
Faculty:
Jones Nauseef, MD, PhD
Assistant Professor of Medicine
Division of Hematology & Medical Oncology
Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Nauseef has served as a consultant for AIQ, Bayer, and Pfizer.
He has served on an advisory board for Bayer and Pfizer. All
relevant conflicts of interest have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by educational grants from
Merck Sharp & Dohme LLC and Seagen
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |